Zika virus Therapeutics: Drug Targets and Repurposing Medicine from the Human Genome
Open Access
- 3 March 2016
- journal article
- Published by MedCrave Group Kft. in MOJ Proteomics & Bioinformatics
- Vol. 3 (3) , 1-7
Abstract
Zika viral infection is caused by an emerging mosquito-borne virus, the Zika virus (ZIKV) and threatens to become a global pandemic. While not life threatening, the Zika Virus Disease (ZVD) is suspected to be associated with severe neurological disorders including Guillain-Barré syndrome and microcephaly. Currently, no known cure or diagnostic tests for ZVD are available. The host cell molecular targets are unknown for ZIKV. The ZIKV is related to various other mosquito borne viruses including the Chikungunya, Dengue, Japanese encephalitis, Spondweni, Yellow fever and West Nile viruses. The host cell targets are known for most of these viruses. All of these viruses harbor common protein motifs and domains, raising the possibility of shared molecular targets in the host genome. To facilitate target(s) discovery for the ZIKV therapy, the disease-and protein-knowledge databases were datamined for Zika-related viruses. An initial database of 251 genes was established. Additional filtering using variants associated with the Zika-related viruses and neurological disease phenotypes, identified 55 putative candidate ZIKV targets. These encompass druggable proteins including adhesion molecules, chemokines, enzymes, interleukins, receptors and transporters. Genes linked to Guillain-Barré syndrome and microcephaly was among the Zika candidate genes. The protein expression of the candidate genes was detected in diverse body fluids. Drug bank datamining of these candidate targets identified seventy-nine FDA-approved drugs of the class antineoplastics, anti diabetic, anti-inflammatory, antivirals, antibiotics, statins and neutraceuticals. The database of genes from the study provides a framework for diagnosis and therapy of the ZVD. The FDA-approved list of drugs, if verified, may offer a repurposing use for the treatment of the ZVD.Keywords
This publication has 44 references indexed in Scilit:
- Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case studyThe Lancet Infectious Diseases, 2016
- Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg?Ultrasound in Obstetrics & Gynecology, 2016
- Zika virus genome from the AmericasThe Lancet, 2016
- Phenotype–Genotype Integrator (PheGenI): synthesizing genome-wide association study (GWAS) data with existing genomic resourcesEuropean Journal of Human Genetics, 2013
- Pharmacogenomics Knowledge for Personalized MedicineClinical Pharmacology & Therapeutics, 2012
- Emerging host cell targets for hepatitis C therapyDrug Discovery Today, 2007
- Full-length sequencing and genomic characterization of Bagaza, Kedougou, and Zika virusesArchives of Virology, 2007
- The Discovery of the CCR5 Receptor Antagonist, UK-427,857, A New Agent for the Treatment of HIV Infection and AIDS2005
- Zika virus, a cause of fever in Central Java, IndonesiaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1981
- Zika virus infections in Nigeria: virological and seroepidemiological investigations in Oyo StateEpidemiology and Infection, 1979